What is the appropriate management of acute hepatitis A, B, and C, including recommended medications, dosages, routes of administration, side effects, and contraindications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Hepatitis: Medications, Dosages, Routes, Side Effects, and Contraindications

Hepatitis A

Acute hepatitis A is a self-limited disease requiring only supportive care, as no virus-specific antiviral treatment has been proven effective 1. Management focuses on symptom relief and monitoring for complications.

Treatment Approach

  • Supportive care only: High-calorie diet, bedrest if symptomatic, adequate hydration
  • Avoid hepatotoxic medications (especially acetaminophen) and alcohol 2
  • Hospitalization if unable to maintain oral intake due to nausea/vomiting or if mental status changes suggest fulminant hepatic failure 3
  • Monitor for fulminant liver failure: Serial ALT, bilirubin, INR, and mental status assessment
  • Liver transplantation may be lifesaving in rare cases of fulminant hepatic failure 1

Key Contraindications

No specific antiviral contraindications exist, but avoid all hepatotoxic substances during acute illness.


Hepatitis B

Acute Hepatitis B

Acute hepatitis B typically resolves spontaneously in 95% of immunocompetent adults and requires only supportive care 4. However, nucleoside analogs may be considered in specific circumstances.

Treatment Approach

  • Supportive care is the primary management for most cases 1
  • Consider lamivudine 100 mg orally daily in severe acute hepatitis B, though not subjected to controlled trials 1, 3
  • Monitor for spontaneous clearance: Check HBsAg, HBV DNA, and ALT every 4-8 weeks for 6 months 2
  • Initiate antiviral therapy if progression to chronic infection occurs (HBsAg positive >6 months)

Chronic Hepatitis B

Treatment of chronic hepatitis B aims to suppress viral replication and prevent progression to cirrhosis and hepatocellular carcinoma 5. High genetic barrier nucleoside analogs are preferred.

Recommended Medications & Dosages

First-line agents (high genetic barrier):

  • Entecavir (ETV): 0.5 mg orally once daily (1 mg daily if lamivudine-experienced)
  • Tenofovir disoproxil fumarate (TDF): 300 mg orally once daily
  • Tenofovir alafenamide (TAF): 25 mg orally once daily

Alternative (lower barrier to resistance):

  • Lamivudine: 100 mg orally once daily 6
  • Adefovir: Used as alternative but less preferred 6

Route of Administration

All chronic HBV medications are administered orally, once daily.

Treatment Duration

  • Indefinite therapy is typically required for most patients with chronic HBV
  • Post-liver transplant prophylaxis: Continue nucleoside analog indefinitely, combined with hepatitis B immunoglobulin (HBIG) during anhepatic phase, with HBIG dosing adjusted to maintain anti-HBs levels 7
  • Immunosuppression prophylaxis: Continue for at least 6-12 months after immunosuppressive therapy ends; extend to 18 months after B-cell depleting therapy (e.g., rituximab) 7

Side Effects

  • TDF: Renal impairment, decreased bone mineral density, Fanconi syndrome
  • TAF: Better renal and bone safety profile than TDF
  • Entecavir: Generally well-tolerated; lactic acidosis (rare)
  • Lamivudine: High rate of resistance with prolonged use (up to 70% at 5 years)

Contraindications

  • Severe renal impairment (eGFR <30 mL/min): Requires dose adjustment for all nucleoside analogs
  • Pregnancy considerations: TDF and TAF are preferred during pregnancy
  • Decompensated cirrhosis: Not a contraindication; treatment is indicated

Special Populations

  • Reactivation prevention: HBsAg-positive patients starting chemotherapy or immunosuppression should receive prophylactic nucleoside analog therapy 1
  • Monitor HBV DNA every 3 months during immunosuppression in HBsAg-negative/anti-HBc-positive patients 7

Hepatitis C

Acute Hepatitis C

Treatment of acute hepatitis C should follow the same direct-acting antiviral (DAA) regimens as chronic infection, though monitoring for spontaneous clearance for 12-16 weeks is reasonable before initiating therapy 2.

Initial Management

  • Monitor for spontaneous clearance: Check HCV RNA and ALT every 4-8 weeks for minimum 6 months 2
  • Spontaneous clearance occurs in only 25% of acute cases 4
  • If treatment is initiated early, monitor HCV RNA for at least 12-16 weeks to detect spontaneous clearance before starting therapy 2
  • Counsel patients to avoid hepatotoxic drugs and alcohol; refer injection drug users to addiction medicine 2

Treatment Regimens

Use the same DAA regimens as chronic hepatitis C (see below).

Alternative (historical, less preferred):

  • Pegylated interferon ± ribavirin for 16-24 weeks 2

Chronic Hepatitis C

All HCV-infected patients without contraindications should be considered for treatment, with priority given to those with advanced fibrosis (≥F3), decompensated cirrhosis, and pre/post-transplant patients 5. Modern DAA therapy achieves >90% cure rates.

Pangenotypic Regimens (All Genotypes 1-6)

Option 1: Sofosbuvir/Velpatasvir (Preferred)

  • Dosage: Fixed-dose combination of sofosbuvir 400 mg + velpatasvir 100 mg orally once daily 8, 9
  • Duration: 12 weeks for most patients 8, 9
  • Treatment-naïve and treatment-experienced patients without cirrhosis or with compensated cirrhosis: 12 weeks without ribavirin 8

Option 2: Glecaprevir/Pibrentasvir

  • Dosage: Fixed-dose combination of glecaprevir 300 mg + pibrentasvir 120 mg orally once daily 9
  • Duration: 8-12 weeks depending on treatment history and cirrhosis status 9

Genotype-Specific Regimens

Genotype 1,4,5,6:

  • Ledipasvir/Sofosbuvir: Fixed-dose combination of ledipasvir 90 mg + sofosbuvir 400 mg orally once daily for 12 weeks 9
  • Grazoprevir/Elbasvir: Grazoprevir 100 mg + elbasvir 50 mg orally once daily for 12 weeks 8

Genotype 2:

  • Sofosbuvir/Velpatasvir: 12 weeks without ribavirin 8
  • Sofosbuvir/Daclatasvir: Sofosbuvir 400 mg + daclatasvir 60 mg orally once daily for 12 weeks without ribavirin 8

Genotype 3:

  • Sofosbuvir/Velpatasvir: 12 weeks 8
    • Add weight-based ribavirin (1000 mg if <75 kg; 1200 mg if ≥75 kg daily) for treatment-experienced patients or those with compensated cirrhosis, unless NS5A RAS Y93H is absent 8
    • 24 weeks without ribavirin if ribavirin contraindicated 8
  • Sofosbuvir/Daclatasvir: 12 weeks with ribavirin for treatment-experienced or cirrhotic patients 8

Route of Administration

All DAAs are administered orally, once daily.

Ribavirin Dosing (When Added)

  • Weight-based: 1000 mg daily (<75 kg) or 1200 mg daily (≥75 kg), divided into two doses 8
  • Decompensated cirrhosis: Start at 600 mg daily and adjust based on tolerance 8
  • Severe renal impairment: 200 mg daily if hemoglobin >10 g/dL 8

Side Effects

DAAs (generally well-tolerated):

  • Sofosbuvir-based regimens: Headache, fatigue, nausea (common but mild)
  • Protease inhibitors (grazoprevir, paritaprevir): Hyperbilirubinemia, hepatotoxicity
  • Glecaprevir/pibrentasvir: Headache, fatigue, nausea

Ribavirin:

  • Hemolytic anemia (dose-limiting): Monitor hemoglobin frequently; discontinue if <8.5 g/dL 8
  • Fatigue, rash, pruritus
  • Teratogenic: Absolute contraindication in pregnancy and partners of pregnant women

Pegylated Interferon (historical, rarely used):

  • Flu-like syndrome, injection site reactions
  • Neuropsychiatric disorders (depression, suicidal ideation)
  • Cytopenias, autoimmune phenomena
  • Thyroid dysfunction 5, 6

Contraindications

Sofosbuvir:

  • Severe renal impairment (eGFR <30 mL/min/1.73 m²): Use with extreme caution; no dose recommendation available 5, 8
  • Monitor renal function closely; discontinue immediately if deterioration occurs 8

Protease Inhibitors (paritaprevir, dasabuvir, asunaprevir):

  • Decompensated cirrhosis (Child-Pugh B or C): Contraindicated due to markedly increased drug concentrations 5

Grazoprevir/Elbasvir:

  • Cyclosporine co-administration: Contraindicated (15-fold increase in grazoprevir levels) 9, 10
  • Strong CYP3A inducers (efavirenz, etravirine, carbamazepine, phenytoin, St. John's wort): Contraindicated 10

Ribavirin:

  • Pregnancy: Absolute contraindication (teratogenic) 5
  • Severe anemia (hemoglobin <10 g/dL at baseline)
  • Severe cardiac disease
  • Autoimmune hepatitis
  • Uncontrolled psychiatric illness 5

Pegylated Interferon (historical):

  • Decompensated cirrhosis
  • Uncontrolled depression or psychiatric illness
  • Uncontrolled autoimmune diseases
  • Solid organ transplantation (except liver)
  • Pregnancy
  • Age ≤2 years
  • Severe concurrent medical illness (poorly controlled hypertension, heart failure, significant coronary disease, poorly controlled diabetes, COPD) 5

Special Populations

Severe Renal Impairment (eGFR <30 mL/min) or Hemodialysis:

  • Genotype 1a: Grazoprevir/elbasvir for 12 weeks with ribavirin 200 mg/day (if Hgb >10 g/dL) OR ritonavir-boosted paritaprevir/ombitasvir/dasabuvir for 12 weeks with ribavirin 200 mg/day 8
  • Genotype 1b: Grazoprevir/elbasvir for 12 weeks without ribavirin OR ritonavir-boosted paritaprevir/ombitasvir/dasabuvir for 12 weeks without ribavirin 8
  • Genotype 4: Ritonavir-boosted paritaprevir/ombitasvir for 12 weeks with ribavirin 200 mg/day OR grazoprevir/elbasvir for 12 weeks without ribavirin 8
  • Treat in expert centers with multidisciplinary monitoring 8

Decompensated Cirrhosis (Child-Pugh B or C):

  • Sofosbuvir/Velpatasvir: 12 weeks with weight-based ribavirin (start 600 mg daily, adjust for tolerance) 8
  • Sofosbuvir/Ledipasvir (genotypes 1,4,5,6): 12 weeks with ribavirin 8
  • Sofosbuvir/Daclatasvir: 12 weeks with ribavirin 8
  • Avoid protease inhibitors (contraindicated) 5
  • 24 weeks without ribavirin if ribavirin contraindicated or not tolerated 8

Post-Liver Transplant:

  • Initiate treatment early (ideally after first 3 months post-transplant when patient stabilized) 8
  • Genotype 1,4,5,6: Sofosbuvir/ledipasvir or sofosbuvir/daclatasvir for 12 weeks with weight-based ribavirin 8
  • Genotype 2: Sofosbuvir/daclatasvir for 12 weeks with ribavirin 8
  • Genotype 3: Sofosbuvir/daclatasvir for 24 weeks with ribavirin 8
  • Monitor immunosuppressant levels closely; no dose adjustments needed except possibly everolimus 8
  • Avoid protease inhibitors due to drug-drug interactions with immunosuppressants 8

HIV Coinfection:

  • Sofosbuvir/velpatasvir: Compatible with most antiretrovirals 8
  • Glecaprevir/pibrentasvir: Contraindicated with atazanavir and not recommended with other HIV protease inhibitors or efavirenz/etravirine/nevirapine 10
  • Grazoprevir/elbasvir: Limited antiretroviral compatibility; can use with nucleotide RTIs, rilpivirine, raltegravir, dolutegravir, maraviroc, doravirine, bictegravir, cabotegravir 10
  • Thorough drug-drug interaction assessment required before starting therapy 10

HCV-Negative Recipients of HCV-Viremic Organ Donors:

  • Initiate DAA therapy as early as clinically possible (prophylactic/preemptive or reactive approach) 9
  • Pangenotypic regimen required for prophylactic approach: Glecaprevir/pibrentasvir or sofosbuvir/velpatasvir for 12 weeks 9
  • Avoid protease inhibitors in moderate-severe liver dysfunction 9
  • Monitor calcineurin inhibitor levels closely; avoid elbasvir/grazoprevir with cyclosporine 9

Critical Drug-Drug Interactions

A thorough drug-drug interaction assessment is mandatory before starting DAA therapy and before adding any new medications during treatment 10. Key resources include www.hep-druginteractions.org.

High-Risk Interactions

  • Amiodarone + sofosbuvir: Contraindicated (risk of severe bradycardia)
  • Cyclosporine + grazoprevir/elbasvir: Contraindicated
  • Strong CYP3A inducers (rifampin, carbamazepine, phenytoin, St. John's wort): Contraindicated with most protease inhibitors
  • High-dose proton pump inhibitors: Contraindicated or not recommended with ledipasvir
  • Certain statins (atorvastatin, simvastatin): Dose adjustments or monitoring required with protease inhibitors
  • Tacrolimus levels: Monitor closely with all DAAs; 40-50% increase expected with grazoprevir/elbasvir 9

Common Pitfalls to Avoid

  1. Do not use sofosbuvir in severe renal impairment (eGFR <30) without careful consideration and close monitoring 5, 8
  2. Do not use protease inhibitors in decompensated cirrhosis 5
  3. Do not combine grazoprevir/elbasvir with cyclosporine 9
  4. Monitor hemoglobin frequently when using ribavirin; discontinue if <8.5 g/dL 8
  5. Ensure adequate contraception for 6 months after ribavirin discontinuation (both patient and partner) 5
  6. Check drug-drug interactions before prescribing DAAs, especially in HIV-coinfected patients 10
  7. Do not delay treatment in acute hepatitis C beyond 6 months if spontaneous clearance has not occurred 2
  8. Prioritize treatment in patients with advanced fibrosis (≥F3), decompensated cirrhosis, pre/post-transplant, and severe extrahepatic manifestations 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.